Sign inCreate account

Report workspace tools

NCT00223509COMPLETEDanonymous

Lamictal As Add on Treatment in Mixed States of Bipolar Disorder

Sponsor

Source record

The University of Texas Health Science Center at San Antonio

Phase

Source record

PHASE4

Modality

AI-normalized

small molecule

Target

AI-normalized

Lamotrigine

Indication / condition

AI-normalized

Bipolar Disorder

Intervention

Source record

Lamotrigine

Source & freshness

Source record

NCT ID

NCT00223509

Original source

ClinicalTrials.gov

Source last updated

Jun 20, 2012

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00223509

Title

Lamictal As Add on Treatment in Mixed States of Bipolar Disorder

Sponsor

The University of Texas Health Science Center at San Antonio

Status

COMPLETED

Phase

PHASE4

Condition raw

Bipolar Disorder

Condition normalized

Bipolar Disorder

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Lamotrigine

Target normalized

Lamotrigine

Interventions

Lamotrigine

Public preview

Source record

To evaluate the efficacy and safety of LAM+existing regimen of mood stabilizer in the acute treatment of patients in a mixed state of bipolar disorder.

To evaluate the efficacy and of a combination of LAM+existing regimen of mood stabilizers in the maintenance treatment of patients with mixed state of bipolar disorder

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Lamictal As Add on Treatment in Mixed States of Bipolar Disorder

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00223509

Status

COMPLETED

Phase

PHASE4

Sponsor

The University of Texas Health Science Center at San Antonio

Executive brief

Investment-Ready Snapshot

* To evaluate the efficacy and safety of LAM+existing regimen of mood stabilizer in the acute treatment of patients in a mixed state of bipolar disorder. * To evaluate the efficacy and of a combination of LAM+existing regimen of mood stabilizers in the maintenance treatment of patients with mixed state of bipolar disorder

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 20, 2012
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00223509

Indication

Bipolar Disorder

Modality

small molecule

Target

Lamotrigine

Intervention

Lamotrigine

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.